These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mechanisms of aggregation and fibril formation of the amyloidogenic N-terminal fragment of apolipoprotein A-I. Mizuguchi C; Nakagawa M; Namba N; Sakai M; Kurimitsu N; Suzuki A; Fujita K; Horiuchi S; Baba T; Ohgita T; Nishitsuji K; Saito H J Biol Chem; 2019 Sep; 294(36):13515-13524. PubMed ID: 31341020 [TBL] [Abstract][Full Text] [Related]
4. Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate. Kuwabara K; Nishitsuji K; Uchimura K; Hung SC; Mizuguchi M; Nakajima H; Mikawa S; Kobayashi N; Saito H; Sakashita N J Biol Chem; 2015 Oct; 290(40):24210-21. PubMed ID: 26292220 [TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate remodels apolipoprotein A-I amyloid fibrils into soluble oligomers in the presence of heparin. Townsend D; Hughes E; Akien G; Stewart KL; Radford SE; Rochester D; Middleton DA J Biol Chem; 2018 Aug; 293(33):12877-12893. PubMed ID: 29853648 [TBL] [Abstract][Full Text] [Related]
6. (-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway. Hudson SA; Ecroyd H; Dehle FC; Musgrave IF; Carver JA J Mol Biol; 2009 Sep; 392(3):689-700. PubMed ID: 19616561 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of amyloid fibril formation in the variable domain of λ6 light chain mutant Wil caused by the interaction between its unfolded state and epigallocatechin-3-O-gallate. Abe Y; Odawara N; Aeimhirunkailas N; Shibata H; Fujisaki N; Tachibana H; Ueda T Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2570-2578. PubMed ID: 30251653 [TBL] [Abstract][Full Text] [Related]
8. Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I. Wong YQ; Binger KJ; Howlett GJ; Griffin MD FEBS Lett; 2012 Jun; 586(13):1754-8. PubMed ID: 22609356 [TBL] [Abstract][Full Text] [Related]
9. (-)-epigallocatechin-3-gallate inhibits fibrillogenesis of chicken cystatin. Wang N; He J; Chang AK; Wang Y; Xu L; Chong X; Lu X; Sun Y; Xia X; Li H; Zhang B; Song Y; Kato A; Jones GW J Agric Food Chem; 2015 Feb; 63(5):1347-51. PubMed ID: 25620201 [TBL] [Abstract][Full Text] [Related]
10. A-type dimeric epigallocatechin-3-gallate (EGCG) is a more potent inhibitor against the formation of insulin amyloid fibril than EGCG monomer. Nie RZ; Zhu W; Peng JM; Ge ZZ; Li CM Biochimie; 2016 Jun; 125():204-12. PubMed ID: 27079519 [TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin Gallate Remodels Fibrils of Lattice Corneal Dystrophy Protein, Facilitating Proteolytic Degradation and Preventing Formation of Membrane-Permeabilizing Species. Stenvang M; Christiansen G; Otzen DE Biochemistry; 2016 Apr; 55(16):2344-57. PubMed ID: 27042751 [TBL] [Abstract][Full Text] [Related]
12. Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. Adachi E; Nakajima H; Mizuguchi C; Dhanasekaran P; Kawashima H; Nagao K; Akaji K; Lund-Katz S; Phillips MC; Saito H J Biol Chem; 2013 Jan; 288(4):2848-56. PubMed ID: 23233678 [TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin gallate (EGCG) reduces the intensity of pancreatic amyloid fibrils in human islet amyloid polypeptide (hIAPP) transgenic mice. Franko A; Rodriguez Camargo DC; Böddrich A; Garg D; Rodriguez Camargo A; Rathkolb B; Janik D; Aichler M; Feuchtinger A; Neff F; Fuchs H; Wanker EE; Reif B; Häring HU; Peter A; Hrabě de Angelis M Sci Rep; 2018 Jan; 8(1):1116. PubMed ID: 29348618 [TBL] [Abstract][Full Text] [Related]
14. Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes. Mizuguchi C; Ogata F; Mikawa S; Tsuji K; Baba T; Shigenaga A; Shimanouchi T; Okuhira K; Otaka A; Saito H J Biol Chem; 2015 Aug; 290(34):20947-20959. PubMed ID: 26175149 [TBL] [Abstract][Full Text] [Related]
15. Chameleon 'aggregation-prone' segments of apoA-I: A model of amyloid fibrils formed in apoA-I amyloidosis. Louros NN; Tsiolaki PL; Griffin MD; Howlett GJ; Hamodrakas SJ; Iconomidou VA Int J Biol Macromol; 2015 Aug; 79():711-8. PubMed ID: 26049118 [TBL] [Abstract][Full Text] [Related]
17. Quinopeptide formation associated with the disruptive effect of epigallocatechin-gallate on lysozyme fibrils. Cao N; Zhang YJ; Feng S; Zeng CM Int J Biol Macromol; 2015; 78():389-95. PubMed ID: 25931397 [TBL] [Abstract][Full Text] [Related]
18. Fluphenazine·HCl and Epigallocatechin Gallate Modulate the Rate of Formation and Structural Properties of Apolipoprotein C-II Amyloid Fibrils. Zlatic CO; Mao Y; Ryan TM; Mok YF; Roberts BR; Howlett GJ; Griffin MD Biochemistry; 2015 Jun; 54(24):3831-8. PubMed ID: 26021642 [TBL] [Abstract][Full Text] [Related]
19. Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis. Das M; Mei X; Jayaraman S; Atkinson D; Gursky O FEBS J; 2014 Jun; 281(11):2525-42. PubMed ID: 24702826 [TBL] [Abstract][Full Text] [Related]
20. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. Ferreira N; Cardoso I; Domingues MR; Vitorino R; Bastos M; Bai G; Saraiva MJ; Almeida MR FEBS Lett; 2009 Nov; 583(22):3569-76. PubMed ID: 19861125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]